Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents

References

• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–34
   PubMed Web of Science ®Google Scholar
• Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):11S–26S
   Google Scholar
• PROCRIT® (Epoetin alfa) Prescribing Information. Raritan, NJ: Ortho Biotech Products L.P., 2004
   Google Scholar
• Clark O, Adams JR, Bennett CL, et al. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2:23
   PubMedGoogle Scholar
• Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;29A(Suppl 2):S2–8
   PubMed Web of Science ®Google Scholar
• Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606–17
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–5
   PubMed Web of Science ®Google Scholar
• ARANESP® (Darbepoetin alfa) Prescribing Information. Thousand Oaks, CA: Amgen, Inc., 2003
   Google Scholar
• Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211–20
   PubMed Web of Science ®Google Scholar
• Herrington JD, Davidson SL, Tomita DK, et al. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Am J Health Syst Pharm 2005;62:54–62
   PubMed Web of Science ®Google Scholar
• Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60 000 U once weekly followed by 120 000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004;9:90–6
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412–25
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt) 2002;16:23–9
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268–76
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312–20
   PubMed Web of Science ®Google Scholar
• Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026–34
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 2004;100:859–68
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131–8
   Google Scholar
• Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003;25:2781–96
   PubMed Web of Science ®Google Scholar
• Beveridge RA, Rifkin RM, Moleski RJ, et al. Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy 2003;23:101S–9S
   Google Scholar
• Fahrbach KR, Frame D, Scheye R, et al. Comparison of anemia treatment outcomes in patients with cancer receiving epoetin alfa and darbepoetin alfa. Blood 2003;102:510b [Abstract]
   Google Scholar
• Jaresko G, Gibson G, Dominguez O, et al. Evaluation of the use and outcomes of erythropoietic proteins for the treatment of chemotherapy-induced anemia in the university- affiliated ambulatory setting. Pharmacotherapy 2003;23:1345 [Abstract]
   Google Scholar
• Papatheofanis FJ, Fastenau JM, Chiang TH, et al. Epoetin alfa and darbepoetin alfa anemia treatment outcomes in cancer patients from a Veterans Administration perspective. Value Health 2004;7:246 [Abstract]
   Google Scholar
• Papatheofanis FJ, Fastenau JM, Chiang TH, et al. Management of chemotherapy-related anemia: a study of epoetin alfa and darbepoetin alfa use in a self-insured managed care organization. J Manag Care Pharm 2004;10:196 [Abstract]
   Google Scholar
• Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy induced anemia treated in clinical practice. Oncologist 2004;9:451–8
   Google Scholar
• Grad O, Davis J, Vichare R, et al. Dosing and outcomes study of erythropoiesis-stimulating therapies – D.O.S.E. Support Care Cancer 2004;12:419 [Abstract]
   Google Scholar